Arvinas Inc.
Clinical trials sponsored by Arvinas Inc., explained in plain language.
Biopharmaceutical company developing targeted protein degradation therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets Hard-to-Treat cancer mutation in first human trial Results expected Nov 2026 (estimated)
-
New pill targets Hard-to-Treat lymphoma in first human trial
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ARV-393 in 255 adults with advanced non-Hodgkin's lymphoma that has come back or not responded to other treatments. The drug is taken as a pill and works by breaking down a protein that helps lymphoma grow. The main goals a…
Phase 1 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC